Protective effect of interferon beta on human T cell leukaemia virus type I infection of CD4+ T cells isolated from human cord blood. 1993

B Macchi, and I Faraoni, and A Mastino, and C D'Onofrio, and G Romeo, and E Bonmassar
Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Italy.

The present study shows the effect of human interferon beta (IFN beta) on the susceptibility of highly purified cord blood CD4+ T cells to infection with the human T cell leukaemia virus type I (HTLV-I). Unfractionated cord blood mononuclear cells (CBMC), or a separated CD4+ T cell subpopulation (CBCD4) were exposed to HTLV-I by cocultivation with a chronically infected virus-donor cell line. The results show that presence of proviral DNA as well as virus transcription was markedly reduced by IFN beta in both populations, indicating that this cytokine protects not only unfractionated CBMC but also purified CBCD4 cells from virus infection. Moreover IFN beta treatment caused 60%-80% inhibition of virus expression in CBCD4, assayed as the presence of virus core protein p19. This study demonstrates that IFN beta is able to inhibit HTLV-I infection of CBMC through a mechanism that does not necessarily involve cell-mediated natural or antigen-dependent immunity afforded by CBMC subpopulations distinct from targets of HTLV-I infection. Therefore it is reasonable to conclude that IFN beta has a direct protective effect on CBCD4, through induction of antiviral resistance/activity in target cells.

UI MeSH Term Description Entries
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004790 Enzyme Induction An increase in the rate of synthesis of an enzyme due to the presence of an inducer which acts to derepress the gene responsible for enzyme synthesis. Induction, Enzyme
D005312 Fetal Blood Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery. Cord Blood,Umbilical Cord Blood,Blood, Cord,Blood, Fetal,Blood, Umbilical Cord,Bloods, Cord,Bloods, Fetal,Bloods, Umbilical Cord,Cord Blood, Umbilical,Cord Bloods,Cord Bloods, Umbilical,Fetal Bloods,Umbilical Cord Bloods
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014158 Transcription, Genetic The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION. Genetic Transcription
D014758 Viral Core Proteins Proteins found mainly in icosahedral DNA and RNA viruses. They consist of proteins directly associated with the nucleic acid inside the NUCLEOCAPSID. Core Proteins, Viral,Major Core Protein,Major Core Proteins, Viral,Adenovirus Core Protein VII,Core Protein V,Core Protein lambda 2,Influenza Virus Core Proteins,Major Core Protein lambda 1,Major Core Protein lambda-1,Major Core Protein sigma 2,Major Core Protein sigma-2,OVP 19,Oncornaviral Protein P19,P30 Core Proteins,Viral Protein P19,Virus Core Proteins,Core Protein, Major,Core Proteins, P30,Core Proteins, Virus,Protein P19, Oncornaviral,Protein P19, Viral,Protein, Major Core,Proteins, P30 Core,Proteins, Viral Core,Proteins, Virus Core
D015088 2',5'-Oligoadenylate Synthetase An enzyme that catalyzes the conversion of ATP into a series of (2'-5') linked oligoadenylates and pyrophosphate in the presence of double-stranded RNA. These oligonucleotides activate an endoribonuclease (RNase L) which cleaves single-stranded RNA. Interferons can act as inducers of these reactions. 2',5'-Oligoadenylate Polymerase,2-5A Synthetase,(2'-5')An Polymerase,2',5'-Oligo(A) Polymerase,2',5'-Oligo(A) Synthetase,2,5 Oligoadenylate Polymerase,2,5 Oligoadenylate Synthetase,ATP-(2'-5')oligo(A)adenylyltransferase,2',5' Oligoadenylate Polymerase,2',5' Oligoadenylate Synthetase,Oligoadenylate Polymerase, 2,5,Oligoadenylate Synthetase, 2,5,Polymerase, 2',5'-Oligoadenylate,Polymerase, 2,5 Oligoadenylate,Synthetase, 2',5'-Oligoadenylate,Synthetase, 2,5 Oligoadenylate
D015368 Human T-lymphotropic virus 1 A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC). ATLV,Adult T-Cell Leukemia-Lymphoma Virus I,HTLV-1,HTLV-I,Human T-Cell Leukemia Virus I,Leukemia Virus I, Human T-Cell,T-Cell Leukemia Virus I, Human,Adult T Cell Leukemia Lymphoma Virus I,Human T Cell Leukemia Virus I,Leukemia Lymphoma Virus I, Adult T Cell,Leukemia Virus I, Human T Cell,T Cell Leukemia Virus I, Human,Human T lymphotropic virus 1
D015490 HTLV-I Infections Diseases caused by HUMAN T-LYMPHOTROPIC VIRUS 1. Human T-lymphotropic Virus 1 Infection,Human T-lymphotropic Virus 1 Infections,Infections, HTLV-I,HTLV I Infections,HTLV-I Infection,Human T lymphotropic Virus 1 Infection,Human T lymphotropic Virus 1 Infections,Infection, HTLV-I,Infections, HTLV I

Related Publications

B Macchi, and I Faraoni, and A Mastino, and C D'Onofrio, and G Romeo, and E Bonmassar
January 1997, The Journal of general virology,
B Macchi, and I Faraoni, and A Mastino, and C D'Onofrio, and G Romeo, and E Bonmassar
October 2014, The Lancet. Oncology,
B Macchi, and I Faraoni, and A Mastino, and C D'Onofrio, and G Romeo, and E Bonmassar
March 1991, British journal of haematology,
B Macchi, and I Faraoni, and A Mastino, and C D'Onofrio, and G Romeo, and E Bonmassar
November 2004, Comptes rendus biologies,
B Macchi, and I Faraoni, and A Mastino, and C D'Onofrio, and G Romeo, and E Bonmassar
February 2008, Journal of virology,
B Macchi, and I Faraoni, and A Mastino, and C D'Onofrio, and G Romeo, and E Bonmassar
June 2004, British journal of haematology,
B Macchi, and I Faraoni, and A Mastino, and C D'Onofrio, and G Romeo, and E Bonmassar
February 2004, Journal of immunology (Baltimore, Md. : 1950),
B Macchi, and I Faraoni, and A Mastino, and C D'Onofrio, and G Romeo, and E Bonmassar
January 2007, Reviews in medical virology,
B Macchi, and I Faraoni, and A Mastino, and C D'Onofrio, and G Romeo, and E Bonmassar
June 2010, Immunopharmacology and immunotoxicology,
B Macchi, and I Faraoni, and A Mastino, and C D'Onofrio, and G Romeo, and E Bonmassar
October 1993, Current opinion in neurobiology,
Copied contents to your clipboard!